

# ISNS 2016 BIANNUAL MEETING

The sentinel Node in the era  
of individualized management  
of cancer patients.

[www.isnsmeeting2016.org](http://www.isnsmeeting2016.org)

APRIL 30TH-MAY 2ND  
MILAN - ITALY

## CHAIRMEN



**Nicola Mozzillo MD**

Director Department Melanoma  
and Soft Tissue  
Scientific Vice Director  
Istituto Nazionale dei Tumori di Napoli  
email: [nimozzi@tin.it](mailto:nimozzi@tin.it)



**Alessandro Testori MD**

Chairman EORTC Melanoma  
Group 2012-2014  
Chairman chirurgia/surgical subgroup  
EORTC Melanoma Group  
Director  
Dermato-oncological division  
Istituto Europeo di Oncologia  
[alessandro.testori@ieo.it](mailto:alessandro.testori@ieo.it)



## ISNS 2016 BIANNUAL MEETING

APRIL 30TH | Istituto Europeo di Oncologia - via ripamonti, 435 Milan |

MAY 1ST - 2ND | Nhow Hotel - via tortona, 35 Milan | [info.nhow@nh-hotels.com](mailto:info.nhow@nh-hotels.com) | +39 024898861





## **The sentinel Node in the era of individualized management of cancer patients**

The International Sentinel Node Society serves and coordinates the needs of the diverse community of physicians and scientists who study the sentinel node. It is now clear that the sentinel node concept, as originally described in patients with melanoma, is applicable to any type of malignant tumor that has the potential to spread via lymphatics to lymph nodes. Thus sentinel node technology has now entered a new phase of discovery and treatment. This technique has great potential for individualized management of solid tumors and it is also apparent that successful application of sentinel node technology requires close cooperation between dermatologist, surgeons, pathologists, radiologists and nuclear medicine physicians.

The new era of the SNB concept should be to perform this procedure both to evaluate the real necessity to perform a radical nodal dissection as it has been demonstrated for many patients with breast cancer and to drive clinicians to prescribe new adjuvant therapies with molecular based targeting or immunologically based approaches.

These medical therapies topic is becoming more and more important in the advanced disease setting, which makes the adjuvant setting the new topic to be explored and proposed for clinical research proposals.

Similarly apart the consolidates approach in melanoma and breast cancer, a clear identification on the role of SNB in most solid tumors needs to obtain a definitive validation: guide lines discussion will be conducted on all these diseases where such procedure has not reached a well defined profile and indication.

## April 30

Istituto Europeo di Oncologia, Via Ripamonti, 435 Milano - Room Direzione Scientifica

**13:00** Board meeting of the steering committee

### Plenary Session

**14:00** Registration

**15:30** Opening Ceremony

*Chairmen N. Mozzillo,  
A. Testori and J. Gershenwald*

**16:00** Welcome message

*M. Melis  
G. Ciliberto  
S. Lodato  
R. Orecchia*

**16:30** A tribute to Donald Morton

*M. Faries*

**16:40** A tribute to Natale Cascinelli

*A. Testori*

**16:50** A life dedicated to conservative surgery

*U. Veronesi*

**17:00** AJCC melanoma staging system: towards a 8th edition

*J. Gershenwalds*

**17:10** Break

### SNB: future prospectives

**Chairmen** C.M. Balch  
P. Delrio

**17:20** Melanoma

*N. Mozzillo*

**17:30** Breast

*H. Cody III*

**17:40** Head & Neck

*R. Martin*

**17:50** Gastro intestinal

*Y. Kitagawa*

**18:00** Colorectal

*S. Saha*

**18:10** Urology

*H.G. van Der Poel*

**18:20** Gynecology

*S. Gregg*

**18:30** The role of sentinel node in the future of cancer management

*C.M. Balch*

**18:45** Assembly Report

*J. Gershenwald*

**19:20** Cocktail dinner (transfer by bus to Testori's family country house)

**May 1**

**Room MIAMI - PANAMA - DUBAI**

Nhow Hotel, Via Tortona 35, Milano

**Plenary Session**

**Sentinel Node and Technologies**

**Chairmen** S. Lastoria  
S. Vidal Sicar

<b>08:30</b>	Overview of Lymphoscintigraphy	<i>R. Uren</i>
<b>08:45</b>	Enhanced receptor-targeting with Tilmanocept for lymphatic mapping	<i>A. Wallace</i>
<b>09:00</b>	Hybrid tracers for combined radioactivity/fluorescence detection	<i>F. van Leeuwen</i>
<b>09:15</b>	Indocyanine Green for Fluorescence Imaging	<i>K. Joachim</i>
<b>09:30</b>	SPECT/CT for preoperative sentinel lymph node localization in areas of complex anatomy	<i>R. Valdés Olmos</i>
<b>09:45</b>	Sestamibi-guided biopsy of radiologically occult breast lesions using dedicated gamma camera devices	<i>L. Pereira Arias</i>
<b>10:00</b>	Sentinel node biopsy in early stage breast cancer with a single incision and no lymphoscintigraphy	<i>M. Rizzo</i>
<b>10:15</b>	Fluorescent identification of sentinel node in the invisible light range	<i>R. Andtbacka</i>
<b>10:30</b>	Discussion	
<b>10:45</b>	Break	

**May 1**

**Room MIAMI - PANAMA**

**Plenary Session**

Sentinel Node Biopsy pathologists session towards a consensus on SN sectioning

**Chairmen** A. Cochran  
G. Viale

<b>11:00</b>	The EORTC sectioning protocol	<i>S. Koljenovic</i>
<b>11:15</b>	The UCLA sectioning protocol	<i>A. Cochran</i>
<b>11:30</b>	The Australian Sectioning Protocol	<i>L. Jackett</i>
<b>11:45</b>	ITC Identification and biological significance in breast	<i>A. Sapino</i>
<b>12:00</b>	Augsburg/Rotterdam classification of Melanoma SLN metastases and its prognostic value	<i>H. Starz</i>
<b>12:15</b>	Are SN data bases comparable?	<i>A. Van Akkooi</i>
<b>12:30</b>	Intraoperative frozen sectioning in breast and melanoma	<i>PRO &amp; CON - A. Spatz</i>
<b>12:45</b>	SLN status and computational image analyses	<i>R. Riber-Hansen</i>
<b>13:00</b>	Discussion	
<b>13:15</b>	Lecture: Follow up randomized study on melanoma: update	<i>A. Testori</i>
<b>13:30</b>	Lunch	
<b>13.45 - 14.45</b>	Satellite symposium by Ithera medical	

**May 1**

**Room MIAMI - PANAMA**

Microstaging and clinical decisions

**Chairmen** R. Andtbacka  
D. Massi

- 14:45** Histopathology of positive SNB and long term outcomes *A. Cochran*
- 15:00** Clinical role of ITC in SLN *C. R. Rossi*
- 15:15** Cancer metastasis from tumor microenvironment to the sentinel lymph node *S. Leong*
- 15:30** Correlation between sentinel node status and mutational profile in melanoma *G. Botti*
- 15:45** Confocal microscopy may help to select thin melanoma patients for SNB? *G. Pellacani*
- 16:00** Is completion LND indicated? *PRO - M. Ross  
CON - D. Coit*
- 16:30** Discussion
- 16:45** Break

**May 1**

**Room MIAMI - PANAMA**

**Sentinel Node Biopsy melanoma session**

**Chairmen** N. Mozzillo  
A. Testori

- 17:00** The role of sentinel node staging in the design and end results reporting of cancer clinical trial *J. Thompson*
- 17:15** SLN for atypical melanocytic neoplasms *M. Yamamoto*
- 17:30** Is there a good timing for SLN biopsy? *A. Tejera-Vaquerizo*
- 17:45** Management of patients with positive nodes on an ectopic location of the sentinel node (epitrochlear, popliteal, trunk) *C. Caracò*
- 18:00** Role of guided FNA in diagnosis and prognosis *O. Catalano*
- 18:15** From open to minimally invasive lymphadenectomy: learning curve and results in quality of life *J. Soteldo*
- 18:30** Discussion
- 18:45** Closure



May 1

## Room DUBAI

11:00 - 13:00 Abstract presentations and new studies proposed

### 11:00 - 12:00 Technologies

**Chairmen** P.M. Herranz, C. Grana

**1. Real time integration of freehand SPECT and ultrasound for preoperative localization of sentinel lymph nodes**

*C Bluemel, G Safak, AK Buck, K Herrmann*

**2. Lymphovascular anastomosis (lymphatic technique)**

*F Boccardo, G Villa, F Casabona, CC Campisi, S Dessalvi, L Molinari, S Spinaci, C Cornacchia, M Valenzano, S Costantini, D Friedman, F Murelli, F De Cian, C Campisi*

**3. Sentinel node mapping using unique multimodality probes**

*H Fujii, K Ohnuki, K Araki, Y Tanaka, S Hamamichi, A Fujit, Io Umeda, S Kosuda, A Shiotani*

**4. First in human use of the prototype opto nuclear probe, a hybrid modality that allows for sequential radio and near infrared fluorescence tracing during surgery**

*NS van den Berg, H Simon, GH KleinJan, T Engelen, A Bunschoten, MN Welling, BM Tijink, S Horenblas, J Chambron, FWB van Leeuwen*

**5. Factors Influencing the Sentinel Lymph Node Count: who is your pathologist?**

*JT Unkart, AM Wallace*

**6. Ph Transistor Nanoprobes for Fluorescence Detection of Occult Nodal Metastases**

*B Sumer, J Thibodeaux, Z Lin, T Zhao, G Huang, GC. Balch, J Gao, CM Balch*

**7. Development of a practical 10 min intraoperative IHC product line**

*Y Zhang, Z Zhang, J Wang, S Zhao, F Lin*

**8. The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using verteporfin nanoparticles.**

*H Jinno, S Matsuda, K Shimada, T Konno, K Ishihara, Y Kitagawa*

May 1

## Room DUBAI

12:00 - 13:00 Technologies

Chairmen S. Lastoria, R. Uren

**1. To facilitate hybrid surgical guidance, does hardware integration of gamma and fluorescence imaging modalities make sense in the operating room?**

*GH KleinJan, D Hellingman, NS van den Berg, MN van Oosterom, J Catret, S Horenblas, RA Valdes Olmos, FWB van Leeuwen*

**2. Near infrared fluorescence guided surgery: determination of the lower detection limit at which intraoperative fluorescence guidance is still feasible**

*GH KleinJan, A Bunschoten, NS van den Berg, RA Valdes Olmos, VMC Klop, S Horenblas, HG van der Poel, HJ Wester, FWB van Leeuwen*

**3. Multispectral fluorescence imaging to generate a patient specific road map as a means to improve fluorescence guided surgery**

*NS van den Berg, T Buckle, GH KleinJan, HG van der Poel, FWB van Leeuwen*

**4. A synthetic macromolecule for sentinel node detection: 99mTc DPTA Mannosyl Dextrane**

*DR Vera, AM Wallace, CK Hoh, RF Mattrey*

**5. Lymphoseek: a molecular radiopharmaceutical for sentinel node dissection**

*AM Wallace, CK Hoh, DR Vera, DD Darrah, G Schulteis*

**6. Fluorescent tilmanocept for tumor margin analysis in the mouse model**

*A Hosseini, JL Baker, CA Tokin, Z Qin, DJ Hall, DG StupaK, T Hayashi, AM Wallace, DR Vera*

**7. Optimization via specific fluorescence brightness of a receptor targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes**

*Z Qin, DJ Hall, MA Liss, CK Hoh, CJ Kane, AM Wallace, DR Vera*

**8. Comparative analysis of 1% lymphazurin versus 1% methylene blue for sentinel lymph node mapping in early stage breast cancer**

*S Saha, V Patel, S Grisby, D Mazzaferro, L Berbiglia, G Paez, J Gernand, L Lawrence, D Wiese*

**May 1**

**Room DUBAI**

Sentinel Node in lung cancer

**Chairmen** G. Rocco  
L. Santambrogio

- 14:45** Update on indications and study results *Y.Colson*
- 15:00** Technical devices and new methods to detect SN *G. Rocco*
- 15:15** Staging pathways: SNB or imaging *PRO - Y. Colson*  
*CON - L. Spaggiari*
- 15:30** Update on new therapies on advanced lung cancer *L. Buffoni*
- 15:45** Discussion
- 16:00** Break

May 1

## Room DUBAI

16:10 - 18:30 Abstract presentations and new studies proposed

**Chairmen** P. Delrio, M. Ansarin

**16:10** The treatment of peripheral advanced secondary lymphedema. While the early bird catches the worm, the late riser still benefits *C. C. Campisi*

**16:30 - 17:30** **Gastrointestinal, Urology, Head & Neck**

**1. The Clinical usefulness of the intraoperative detection of sentinel lymph node metastases by a rapid RT PCR system in patients with gastric cancer**

*M Khalid, S Yanagita, Y Uenosono, T Arigami, K Okubo, T Kijima, M Amatatsu, S Natsugoe*

**2. The application of ICG fluorescence sentinel node biopsy for early gastric cancer to the laparoscopic function preserving gastrectomy**

*S Kinami, T Oonishi, Y Fujii, J Fujita, D Kaida, Y Tomita, H Fujita, Y Nakano, N Ueda, T Kosaka*

**3. The sentinel lymph node procedure with isosulfan blue or fluorescence imaging shows comparable upstaging rates in patients with node negative colon cancer - A prospective comparative study**

*B Weixler, A Rickenbacher, DA Raptis, M Zuber*

**4. Non exposed endoscopic wall inversion surgery with sentinel node basin dissection for early gastric cancer**

*A Shimada, H Takeuchi, O Goto, K Fukuda, R Nakamura, T Takahashi, N Wada, H Kawakubo, T Nakahara, K Murakami, M Jinzaki, N Yahagi, Y Kitagawa*

**5. CLEAN NET with Sentinel Node Dissection for Early Gastric Cancer**

*Y Uenosono, T Arigami, K Okubo, S Natsugoe*

**6. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles**

*A Winter, T Kowald, TS Paulo, P Goos, S Engels, H Gerullis, A Chavan, F Wawroschek*

**7. Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects of Sentinel European Node Trial (SENT).**

*G Tartaglione & Sent Group*

**8. Sentinel node biopsy technique in gastrointestinal tract cancer**

*E. Mazza, P Chiaro, M Bellò, P Cassoni, M. Morino, S. Sandrucci, M. Mistrangelo*

**9. Role of hybrid tracer for sentinel lymph node detection in cervical and endometrial cancer**

*P. Paredes, S. Vidal-Sicart, A. Tapias, F. Campos, L. Carballo, P. Fusté, S. Martínez-Román, F. Pons, J. Ordi, J. Pahisa, F. Carmona, F. Lomeña*

May 1

## Room DUBAI

17:30 - 18:30 **Chairmen** F. Di Filippo, R. Andtbacka

**1. Intradermal Stress Lymphoscintigraphy for Screening and Early Detection of Breast Cancer Related Lymphedema.**

*G Tartaglione, R Bartoletti, G Visconti, M Salgarello*

**2. Improved lymphatic mapping for repeat sentinel node biopsy in ipsilateral breast cancer relapse using SPECT/CT**

*P Borrelli, ML Donswijk, MP Stokkel, RA Valdés Olmos*

**3. Innovating radioguided surgery: sentinel node localization in patients with breast cancer using a freehand SPECT mobile gammas camera combination**

*T Engelen, BMF Winkel, DDD Rietbergen, GH KleinJan, S Vidal Sicart, RA Valdes Olmos, NS van den Berg, FWB van Leeuwen*

**4. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy. A study from Dharmais Cancer Hospital**

*B Brahma, RI Putri, RB Andinata, L Sari, SJ Haryono*

**5. Feasibility of Sentinel Lymph Node Biopsy after Ipsilateral Breast Tumor Recurrence.**

*Akiko Matsumoto, Hiromitsu Jinno, Maiko Takahashi, Tetsu Hayashida, Yuko Kitagawa*

**6. PET-CT scan vs Sentinel Node Biopsy in the detection of inguinal lymph-node metastases in patients affected by anal cancer.**

*E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricardi, P. Franco, P. Racca, L. Fanchini, M. Bacciga, P. Chiaro, M. Morino, M. Mistrangelo*

**7. Sentinel node biopsy for anal carcinoma**

*E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricardi, P. Franco, P. Racca, L. Fanchini, P. Chiaro, M. Bacciga, M. Morino, M. Mistrangelo*

**8. The Role Of Pet-Ct Scan In The Detection Of Inguinal Metastases In Patients Affected By Anal Cancer: A Review Of The Literature And A Comparison With Sentinel Node Biopsy And Fine Needle Aspiration**

*E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricard, P. Franco, P. Racca, L. Fanchini, M. Bacciga, M. Morino, M. Mistrangelo*

18:30

Closure

**May 2**

**Room MIAMI - PANAMA**

What after positive sentinel node

**Chairmen** F. Di Filippo  
O.E. Nieweg

**08:30** Value of staging imaging in melanoma patients with positive sentinel lymph nodes *O. E. Nieweg*

**08:45** Completion lymphadenectomy after positive SLN biopsy Melanoma *M. Faries*

**09:00** Breast *F. Di Filippo*

**09:15** Oral Cavity *F. Ionna*

**09:30** Axillary management after neo adjuvant therapy in breast cancer *H. Cody III*

**09:45** Discussion

**10:00** Break

**Chairmen** A. Costa  
D. D'Ugo

**10:15** Adjuvant therapies of SLN + patients: Breast *PRO - E. Munzone  
CON - M. De Laurentiis*

**10:45** Adjuvant therapies of SLN + patients: Melanoma *PRO - V. Chiarion Sileni  
CON - S. Mocellin*

**11:15** Update on immunotherapies in adjuvant and advanced melanoma *P. Ascierto*

**11:30** Update on target therapy in adjuvant and advanced melanoma *P. Queirolo*

**11:45** Video assisted lymphadenectomy *A. Sommariva*

**12:00** Break

**May 2**

**Room MIAMI - PANAMA**

Recurrence and SNB

**Chairmen** J. Gershenwald  
S. Zurrída

**12:15** Follow up for morbidity and recurrence *P. G. Gill*

**12:30** Monitoring sentinel lymph node for circulating tumor cells (CTC) and cell-free circulating DNA/microRNA in melanoma patients *D. Hoon*

**12:45** SNB after melanoma metastases *M. Faries*

**13:00** SNB after breast recurrence *M. Intra*

**13:15** Discussion

**13:30** Lunch

**May 2**

**Room MIAMI - PANAMA**

Sentinel node in Breast cancer

**Chairmen** F. Di Filippo  
P. Veronesi

**14:30** Dedicated PET devices for breast cancer imaging and biopsy *PM. Herranz*

**14:45** Sentinel Node Biopsy: still as a standard treatment in breast cancer surgery? *H. Cody III*

**15:00** The role of SNB after neo adjuvant therapies *V. Galimberti*

**15:15** Technical devices and new methods to detect SN *B. Ballardini*

**15:30** State of the art of SN histological evaluation: still multisection analysis? *L. Jackett*

**15.45** Molecular biology on primary and SNB to indicate adjuvant therapies *A. Spatz*

**16:00** Breast imaging: what's new, what is last *A. Gallipoli  
M. Mattace-raso*

**16:15** Towards a new era on the role of SNB in breast cancer: ongoing studies report *O. Gentilini*

**16:30** Discussion

**16:45** Break



**May 2**

**Room MIAMI - PANAMA**

Sentinel node in H&N cancer

**Chairmen** L. Calabrese  
A. Pastore

- |              |  |                    |
|--------------|--|--------------------|
| <b>17:00</b> | Update on indications and study results                        | <i>F. Ionna</i>    |
| <b>17:15</b> | Molecular patterns detectable from primary disease and SNB     | <i>A. Anichini</i> |
| <b>17:30</b> | Staging pathways: SNB or imaging                               | <i>S. Lastoria</i> |
| <b>17:45</b> | Indications for medical therapy in a multidisciplinary setting | <i>L. Locati</i>   |
| <b>18:00</b> | Discussion   |                    |
| <b>18:15</b> | Closure  |                    |

**May 2**

**Room DUBAI**

08:00 - 09:00 Abstract presentations and new studies proposed

**08:00 - 09:00 Melanoma**

**Chairmen** E. Pennacchioli, G. Di Monta

**1. Is there a single or rare there multiple sentinel lymph nodes for melanoma?**

*DM Balkin, F.Wang, EM. Balkin, C O'Donoghue, M Kashani Sabet, JS Zager, SP Leong*

**2. A portable hybrid camera for fused optical and scintigraphic imaging: clinical experience in melanoma patients**

*S Vidal Sicart, A Bennáassar, A Tapias, P Perlaza, N Sánchez, A Seva*

**3. Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case control study**

*S Ribeiro, C Longo, F Specchio, G Argenziano*

**4. Different measurement of microscopic tumor burden and its prognostic role in sentinel lymph node in patients with cutaneous melanoma**

*G. Di Monta, U. Marone, ML. Di Cecilia, C. Caracò*

**5. The use of a portable gamma camera for the intraoperative detection of additional sentinel nodes in melanoma patients**

*SP Leong, M Wu, Y Lu, D Torre, MA Garrett, M Heller Benson, A Wight, C Ospina, W Lockett, M Kashani Sabet*

**6. When to perform a sentinel lymph node biopsy in thin melanoma?**

*E Gironés, LL Pascual, AC Iturriagagoitia, C E Estébanez*

**7. Report of the use of Tc 99m for SLNB in skin melanoma patients at Surgical Oncology Clinic,**

*NCRC of Serbia, Belgrade, years 2013 2014 2015*

*A Martinovic, N Santrac, M Buta, M Kocic, A Koljević Markovic, S Tasic, R Dzodic*

**8. Quantification of melanoma spread in the sentinel node and survival**

*U. Anja, K. Dietz, I. Hodak, B. Polzer, S. Scheitler, M. Yildiz, C. Zbigniew, P. Lehnert, T. Fehm, C. Hafner, S. Schanz, M. Rothen, C. Garbe, H. Breuninger, G. Fierlbeck, C. Klein*

**May 2**

**Room DUBAI**

**Lymphoedema Following SLN biopsy and TLND**

<b>Chairmen</b>	C. Campisi L. Borgognoni	
<b>09:00</b>	Pre and post-operative evaluation of patients at risk of lymphedema	<i>M. Pinto</i>
<b>09:15</b>	Diagnosis, staging and conservative treatment of Lymphoedema following SNB or TLND.	<i>S.Leong</i>
<b>09:30</b>	Reverse Lymphatic mapping	<i>S. Klimberg</i>
<b>09:45</b>	Lymphovascular anastomosis	<i>F. Boccardo</i>
<b>10:00</b>	Randomized study proposal to prevent lymphedema on groin-axillary	<i>F. De Cian</i>
<b>10:15</b>	Lymph node transplantation	<i>J.H. Dayan</i>
<b>10:30</b>	Discussion	
<b>10:45</b>	Break	

**May 2**

**Room DUBAI**

Sentinel node in abdominal cancer

**Chairmen** F. Corcione  
Y. Kitagawa

- |              |  |  |
|--------------|--|--|
| <b>11:00</b> | Technical devices and new methods  | <i>F. Corcione</i>                         |
| <b>11:15</b> | Update on indications and results in upper G.I.  | <i>H. Takeuchi</i>                         |
| <b>11:30</b> | Update on indications and results in colon   | <i>S. Saha</i>                             |
| <b>11:45</b> | Molecular patterns detectable from primary disease, metastatic lesions and liquid biopsies | <i>A. Bardelli</i>                         |
| <b>12:15</b> | Staging pathways on laparoscopic and robotic approach                                      | <i>PRO P. Bianchi<br/>CON U. Fumagalli</i> |
| <b>12:30</b> | Indications for medical therapy  | <i>A. Avallone</i>                         |
| <b>13:00</b> | Discussion   |  |

May 2

## Room DUBAI

13:15 Lunch and abstract presentation

**13:15 - 14:15**    **Melanoma**

**Chairmen**        C. Caracò, P. Queirolo

**1. Sentinel lymph node mapping using a blue dye as only method tertiary medical center experience**

*D Nikolic, M Granic, M Djorjdevic, A Nikolic*

**2. A 17 year retrospective audit of outcome in patients undergoing sentinel lymph node biopsy in thin melanoma**

*Elena Goni Girones, Jose Rey Vasalo, Juan Ignacio Yanguas Bayona, Carmen Estabanez Estebanez*

**3. Combined analysis of Phase III trials evaluating (99mTc) Tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node negative cutaneous melanoma**

*VK Sondak, DW King, JS Zager, S Schneebaum, J Kim, SPL Leong, MB Faries, BJ Averbook, SR Martinez, CA Pulco, JL Messina, L Christman, AM Wallace*

**4. Gamma probe and Ultrasound Guided Fine Needle Aspiration Cytology of the Sentinel Node in Melanoma and Breast Cancer Patients**

**First Results Pilot GULF Trial.**

*C.M.C. Oude Ophuis, L.B. Koppert, C. de Monyé, S. Koljenović, C.H.M. van Deurzen, C. Verhoef, D.J. Grünhagen*

**5. Fdg pet/ct imaging as a diagnostic tool for progression evaluation of melanoma. Is it really so precise? case report**

*Dejan Nikolic, Zlatko Skuric, Violeta Stanimirovic, Aleksandra Nikolic*

**6. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping**

*AM Wallace, CK Hoh, SJ Ellner, DD Darrah, G Schulteis, DR Vera*

**7. Routine PET/CT and Brain MRI at the time of diagnosis in patients with regional metastatic melanoma rarely identifies systemic disease.**

*EP Miranda, B Jaron, M Kashani Sabet, SPL Leong*

**8. Prospective study on the value of repeat lymphoscintigraphy on the detection of node status in patients undergoing lymph nodal complete radical dissections for melanoma: pilot study and full protocol.**

*A Testori, CR Rossi, G Mazzarol, F Verrecchia, S Gandini, F Cataldo*

**May 2**

**Room DUBAI**

**Sentinel node in gynecologic neoplasms**

**Chairmen** S. Greggi  
M. Thill

**14:30** Update on indications and study results *A. van Der Zee*

**14:45** Technical devices and new methods to detect SN (Paramagnetic particles) *M. Thill*

**15:00** Molecular patterns detectable from primary disease and SNB *G. Palmieri*

**15:15** Staging pathways: SNB or imaging *PRO - N. Abu Rustum  
CON - V. Zanagnolo*

**15:45** Indications for medical therapy in a multidisciplinary setting *N. Colombo*

**16:00** Discussion

**16:15** Break

**May 2**

**Room DUBAI**

**Sentinel node in prostate cancer**

**Chairmen** S. Perdonà  
G. Renne  
F. Wawroschek

- |              |   |                           |
|--------------|---|---------------------------|
| <b>16:30</b> | Update on indications and study results                 | <i>F. Wawroschek</i>      |
| <b>16:45</b> | Technical devices and new methods to detect SN          | <i>H. G. van Der Poel</i> |
| <b>17:00</b> | Atypical lymph node metastatic sites and SLNB           | <i>R. Montironi</i>       |
| <b>17:15</b> | Robotic surgery on prostate cancer+/-SNB                | <i>O. De Cobelli</i>      |
| <b>17:30</b> | Update on immunotherapies on advanced urological cancer | <i>A. Pignata</i>         |
| <b>17:45</b> | Discussion  |                           |
| <b>18:00</b> | Closure   |                           |

Sponsor

**a**genus



**MERCK**








**REGIONE BASILICATA**



**Regione Lombardia**



**REGIONE AUTÒNOMA DE SARDIGNA  
REGIONE AUTONOMA DELLA SARDEGNA**





Con il patrocinio del Ministero della Salute

## Faculty

**Abu Rustum Nadeem**, Memorial Sloan Kettering Cancer Center - New York - USA  
**Andtbacka Robert**, University Of Utah - Salt Lake City - USA  
**Anichini Andrea**, Istituto Nazionale Tumori - Milano - Italia  
**Ansarin Mohssen**, Istituto Europeo di Oncologia - Milano - Italia  
**Ascierto Paolo**, Istituto Nazionale Tumori - Napoli- Italia  
**Avallone Antonio**, Istituto Nazionale Tumori - Napoli - Italia  
**Balch Charles**, University of Texas - Southwestern Medical Center - Dallas - USA  
**Bardelli Alberto**, Istituto Per La Ricerca E Cura Del Cancro Di Candiolo - Torino - Italia  
**Ballardini Bettina**, Istituto Europeo di Oncologia - Milano - Italia  
**Bianchi Paolo Pietro**, Ospedale Civile di Grosseto - Italia  
**Biffi Roberto**, Istituto Europeo di Oncologia - Milano - Italia  
**Boccardo Francesco**, Istituto Nazionale per la ricerca sul cancro - Genova - Italia  
**Borgognoni Lorenzo**, Azienda Ospedaliera Toscana Centro, Italia  
**Botti Gerardo**, Istituto Nazionale Tumori - Napoli - Italia  
**Buffoni Lucio**, Ospedale Molinette - Torino - Italia  
**Calabrese Luca**, Istituto Europeo di Oncologia - Milano - Italia  
**Campisi Corradino**, Istituto Nazionale per la ricerca sul cancro - Genova - Italia  
**Campisi Corrado**, Università Degli Studi Di Genova - Italia  
**Caraco' Corrado**, Istituto Nazionale Tumori - Napoli - Italia  
**Catalano Orlando**, Istituto Nazionale Tumori - Napoli - Italia  
**Chiarion Sileni Vanna**, Istituto Oncologico Veneto - Padova - Italia  
**Ciliberto Gennaro**, Istituto Nazionale Tumori - Napoli - Italia  
**Cochran Alistair**, Ronald Regan Ucla Medical Center - Los Angeles - USA  
**Cody Hiram**, Memorial Sloan Kettering Cancer Center - New York - USA  
**Coit Daniel**, Memorial Sloan Kettering Cancer Center - New York - USA  
**Colleoni Marco**, Istituto Europeo di Oncologia - Milano - Italia  
**Colombo Nicoletta**, Istituto Europeo di Oncologia - Milano - Italia  
**Colson Yolonda**, Brigham & Women's Hospital - Boston - USA  
**Corcione Francesco**, Ospedale Monaldi - Napoli - Italia  
**Costa Alberto**, European School of Oncology - Milano - Italia  
**Dayan Joseph**, Memorial Sloan Kettering Cancer Center - New York - USA  
**De Cian Franco**, Università degli Studi di Genova - Italia  
**De Cobelli Ottavio**, Istituto Europeo di Oncologia - Milano - Italia  
**De Laurentiis Michelino**, Istituto Nazionale Tumori - Napoli - Italia  
**Delrio Paolo**, Istituto Nazionale Tumori - Napoli- Italia  
**Di Filippo Franco**, Istituto Fisioterapico Italiano Regina Elena - Roma - Italia  
**Di Monta Gianluca**, Istituto Nazionale Tumori - Napoli - Italia  
**D'Ugo Domenico**, Ospedale Policlinico Universitario Agostino Gemelli - Roma - Italia  
**Faries Mark**, John Wayne Cancer Institute - Santa Monica - USA  
**Fumagalli Uberto**, Humanitas Reseach Hospital - Milano - Italia  
**Galimberti Viviana Enrica**, Istituto Europeo di Oncologia - Milano - Italia

**Gallipoli D' Enrico Adolfo**, Istituto Nazionale Tumori - Napoli - Italia  
**Gentilini Oreste**, Ospedale San Raffaele - Milano - Italia  
**Gershenwald Jeff**, University of Texas - Md Anderson Cancer Center - Houston - USA  
**Grana Chiara**, Istituto Europeo di Oncologia - Milano - Italia  
**Grantley Gill**, Royal Adelaide Hospital - Adelaide - Australia  
**Greggi Stefano**, Istituto Nazionale Tumori - Napoli - Italia  
**Herranz Michel**, Sergas - Galria - Santiago De Compostela - Spain  
**Hoon Dave**, John Wayne Cancer Institute - Santa Monica - USA  
**Intra Mattia**, Istituto Europeo di Oncologia - Milano - Italia  
**Ionna Franco**, Istituto Nazionale Tumori - Napoli - Italia  
**Jackett Louise**, St. Vincent's Hospital- Melbourne - Australia  
**Joachim Klode**, Universitätsklinikum Essen - Germany  
**Kitagawa Yuko**, Keio University Hospital Tumor Center - Tokyo- Japan  
**Klimberg Susanne**, University of Arkansas - Little Rock - USA  
**Koljenovic Senada**, Erasmus University - Rottendam - Netherlands  
**Lastoria Secondo**, Istituto Nazionale Tumori - Napoli - Italia  
**Leong Stanley**, California Pacific Medical Center Research Institute - San Francisco - USA  
**Locati Laura**, Istituto Nazionale Dei Tumori - Milano - Italia  
**Lodato Sergio**, Commissario Straordinario - Istituto Nazionale Tumori Napoli - Napoli - Italia  
**Massi Daniela**, Università degli Studi di Firenze - Italia  
**Martin Richard**, University Of Aveland - Auckland - New Zealand  
**Mattace-raso Mauro**, Istituto Nazionale Tumori - Napoli - Italia  
**Melis Mauro**, Istituto Europeo di Oncologia - Milano - Italia  
**Mocellin Simone**, Università di Padova - Italia  
**Moncrieff Marc**, Norfolk And Norwich University Hospitals - United Kingdom  
**Montironi Rodolfo**, Università della Marche - Ancona - Italia  
**Mozzillo Nicola**, Istituto Nazionale dei Tumori - Napoli - Italia  
**Munzone Elisabetta**, Istituto Europeo di Oncologia - Milano - Italia  
**Nieweg Omgo**, Melanoma Institute Australia - Sydney - Australia  
**Orecchia Roberto**, Istituto Europeo di Oncologia - Milano - Italia  
**Palmieri Giuseppe**, Cnr - Sassari - Italia  
**Pastore Antonio**, Università di Ferrara - Ferrara - Italia  
**Pellacani Giovanni**, Università degli Studi di Modena e Reggio Emilia - Modena - Italia  
**Pennacchioli Elisabetta**, Istituto Europeo di Oncologia - Milano - Italia  
**Perdonà Sito**, Istituto Nazionale dei Tumori - Napoli - Italia  
**Pereira Arias.Bouda**, Rijnland Hospital - Leiderdorp - Netherlands  
**Pignata Alessandro**, Istituto Nazionale Tumori - Napoli - Italia  
**Pinto Monica**, Istituto Nazionale Tumori - Napoli - Italia  
**Queirolo Paola**, Istituto Nazionale per la ricerca sul cancro - Genova - Italia  
**Renne Giuseppe**, Istituto Europeo Di Oncologia - Milano - Italia  
**Riber-Hansen Rikke**, Aarhus University Hospital - Aarhus - Netherlands  
**Rizzo Monica**, Emory Winship Cancer Center- Atlanta - USA  
**Rocco Gaetano**, Istituto Nazionale Tumori - Napoli - Italia



**Ross Merrick**, Anderson Cancer Center- Houston - USA  
**Rossi Carlo Riccardo**, Istituto Oncologico Veneto - Padova - Italia  
**Saha Sukamal**, McLaren Regional Medical Center - Flint - USA  
**Santambrogio Luigi**, Ospedale Maggiore Policlinico Mangiagalli e Regina Elena - Milano - Italia  
**Sapino Anna**, Fondazione Piemontese per la ricerca sul cancro - Istituto Di Candiolo - Pordenone - Italia  
**Schittulli Francesco**, Presidente Lega Italiana Lotta ai Tumori - Bari - Italia  
**Sommariva Antonio**, Istituto Oncologico Veneto - Padova - Italia  
**Soteldo Javier**, Hospital De Clinicas - Caracas - Venezuela  
**Spaggiari Lorenzo**, Istituto Europeo di Oncologia - Milano - Italia  
**Spatz Alan**, Jewish General Hospital - Montreal - Canada  
**Starz Hans**, Labor Fur Dermatohistologie und Orallpathologie - Munchen - Germany  
**Takeuchi Hiroya**, Keio University - Tokyo - Japan  
**Tejera-Vaquerizo Antonio**, Clinica Dermatologica Globalderm - Cordoba - Spain  
**Testori Alessandro**, Istituto Europeo di Oncologia - Milano - Italia  
**Thill Marc**, Cancer Center at Agaplesion Markus Hospital - Frankfurt- Germany  
**Thompson John**, Royal Prince Alfred Hospital - Camperdown - Australia  
**Uren Roger**, Rpah Medical Center - Newtown - Australia  
**Valdes-Olmos Renato**, Netherlands Cancer Institute - Amsterdam - Netherlands  
**Van Akkooi Alexander**, Netherlands Cancer Institute - Amsterdam - Netherlands  
**Van Der Poel H.G.**, Netherlands Cancer Institute - Amsterdam - Netherlands  
**Van Der Zee Ate**, University Medical Center Groningen - Groningen - Netherlands  
**Van Leeuwen Fijis**, Leiden University Medical Center - Leiden - Netherlands  
**Veronesi Paolo**, Istituto Europeo di Oncologia - Milano - Italia  
**Veronesi Umberto**, Istituto Europeo di Oncologia - Milano - Italia  
**Viale Giuseppe**, Istituto Europeo di Oncologia - Milano - Italia  
**Vidal-Sicart Sergi**, Hospital Clinic de Barcellona - Barcellona - Spain  
**Wallace Anne**, Moores Cancer Center - San Diego - USA  
**Wawroschek Friedheim**, Klinikum Oldenburg - Oldenburg - Germany  
**Yamamoto Maki**, University of California Irvine - Orange - USA  
**Zanagnolo Vanna**, Istituto Europeo di Oncologia - Milano - Italia  
**Zurrida Stefano**, Università degli Studi - Milano - Italia

Participants who wish to submit a poster or oral communication within the Congress, must be sent an abstract within March the 4th 2016:

**Note: the characteristics of the abstract:**

- max 1 page A4
- times New Roman 12 pt

**The structure of the Abstract must be as follows:**

- introduction
- M & M
- results
- conclusion

please, sign up on this page: [www.isnsmeeting2016.org/en/meeting-abstracts](http://www.isnsmeeting2016.org/en/meeting-abstracts)

**ACCOMODATION**

The ISNS 2016 Biannual Meeting organization has entered into the following agreements with these hotels:

<b>HOTEL</b>	<b>PRICE</b>
NHOW Hotel ****	€ 129.00
Hotel Minerva ***	€ 80.00
Hotel Des Etrangers ***	€ 68.00 plus breakfast per night
Hotel Sant'Ambroeus ***	€ 60.00 plus breakfast per night
Isola Libera (B&B)	€ 65.00
Hotel Carrobbio ****	€ 70,00 single room € 100,00 double room



